Inventiva Contemplates The End Of The Road

The group’s MASH candidate lanifibranor carries hefty sales forecasts but Inventiva might run out of cash before the approval trial reports.  

Roadblock
• Source: Shutterstock

Metabolic dysfunction-associated steatohepatitis (MASH) is a very hot area, with some therapies forecasts to sell in the billions and investors impatient for late-stage trial data. But working in this area is not a guarantee of success and there is a very real possibility that MASH specialist Inventiva S.A. will go bankrupt a few months short of completing enrolment in its Phase III trial.

Key Takeaways
  • Inventiva has said it only has enough cash to last to the end of July.

On 5 July Inventiva said that its cash and equivalents, which stand at €19.7m ($21.3m), will run out by the...

More from Clinical Trials

More from R&D